 | |
| Clinical data | |
|---|---|
| Routes of administration |
Topical |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.011.169 |
| Chemical and physical data | |
| Formula | C9H4Cl3IO |
| Molar mass | 361.38 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 113.5 °C (236.3 °F) |
| Solubility in water | Insoluble mg/mL (20 °C) |
| |
| |
| (verify) | |
Haloprogin is an antifungal drug used to treat athlete's foot and other fungal infections. It is marketed in creams under the trade names Halotex, Mycanden, Mycilan, and Polik.
Action
Haloprogin was previously used in 1% topical creams as an antifungal agent. It was marketed over-the-counter primarily to treat tinea infections of the skin. The mechanism of action is unknown.
Haloprogin had a high incidence of side effects including: irritation, burning, vesiculation (blisters), scaling, and itching. It has since been discontinued due to the emergence of more modern antifungals with fewer side effects.